OncoMatch/Clinical Trials/NCT06185205
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
Is NCT06185205 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Accelerated partial breast irradiation for breast cancer.
Treatment: Accelerated partial breast irradiation — The purpose of this study is to compare any good and bad effects of giving radiation treatment for breast cancer in 3 treatments over about 2 days.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Allowed: HER2 (ERBB2) overexpression or amplification
If the tumor is human epidermal growth factor receptor 2 (HER2)-positive, the patient must receive HER2-directed therapy.
Allowed: ESR1 positive
estrogen receptor, Her2 = human epidermal growth factor receptor 2, PR = progesterone receptor negative (ER+PR+HER2-)
Allowed: PR (PGR) positive
estrogen receptor, Her2 = human epidermal growth factor receptor 2, PR = progesterone receptor negative (ER+PR+HER2-)
Allowed: HER2 (ERBB2) negative
estrogen receptor, Her2 = human epidermal growth factor receptor 2, PR = progesterone receptor negative (ER+PR+HER2-)
Disease stage
Required: Stage TIS (TNM)
Grade: G1G2 (Not specified)
T stage of Tis, T1, or T2. T2 tumors must be ≤3 cm in maximum diameter
Demographics
Prior therapy
Must have received: lumpectomy
Previous lumpectomy with surgical margins histologically free of invasive tumor and DCIS as determined by the pathologist.
Cannot have received: breast or thoracic radiation therapy
Prior breast or thoracic radiation therapy (RT) for any condition
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Virginia Commonwealth University · Richmond, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06185205 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior breast or thoracic radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage TIS is required.
Is there an age limit?
Yes. Patients must be 79 years or younger and at least 45 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages